Ovr110 antibody compositions and methods of use
Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
1. A method for inhibiting growth of tumor cells expressing Ovr110, said method comprising contacting the cells with an isolated monoclonal antibody or antigen binding fragment thereof in an amount effective to inhibit growth of the tumor cells, wherein said isolated monoclonal antibody or antigen binding fragment thereof competes with a reference antibody for binding to the epitope on Ovr110 bound by the reference antibody, said reference monoclonal antibody or antigen binding fragment thereof comprising:
(a) a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 12, 22, 32 and 42; and
(b) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7, 17, 27, 37 and 47.
2. The method of claim 1 , wherein the tumor cells are selected from the group consisting of ovarian, uterine, kidney, pancreatic, lung, breast and head and neck tumor cells.
3. The method of claim 1 , wherein the antibody or antigen binding fragment thereof is administered in combination with at least one chemotherapeutic agent.
4. The method of claim 3 , wherein the chemotherapeutic agent is paclitaxel or a derivative thereof.